Patent filing based on research at Hebrew University is latest result of ongoing collaboration with SciSparc Ltd.
VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. CMND, CMNDF, CWY (“Clear head” or the “company“), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve severe undertreated health problems, today announced that it has filed a provisional patent application related to metabolic syndromes including obesity.
The patent application is a further result of the company’s ongoing collaboration with SciSparc Ltd. SPRC (“SciSparc”), a specialty clinical-stage pharmaceutical company focused on developing therapies to treat central nervous system disorders, and with the Hebrew University of Jerusalem.
The patent application is the third filing to result from the collaboration with SciSparc and relates to the proprietary combination of Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s palmitoylethanolamide (PEA), the active ingredient in its proprietary CannAmide™, the is used to treat obesity and related metabolic disorders.
“Food cravings and obesity are an epidemic raging in the United States and around the world, but there are few safe and effective anti-obesity treatments on the market,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind.
“In pre-clinical studies, MEAI has shown great potential in its ability to treat various addictive disorders. Certain metabolic syndromes may be associated with addictive behaviors and we believe the combination of MEAI with SciSparc’s CannAmide™ will provide a valuable tool in the treatment of these disorders could do.”
The study was conducted as part of Clearmind’s research and development projects with the Hebrew University’s Obesity and Metabolism Laboratory, led by Joseph Tam, DMD, Ph.D., Associate Professor of Pharmacology at the university’s Institute for Drug Research.
